

MEDICAL DEVICE STABILITY

**Conducting Package Stability and Performance Validation
for Terminally Sterilized Single-Use Medical Devices**

— and —

Establishing Use-Life for Reusable Medical Devices


Steven Turtil, MS

Microbiology Reviewer, Extracolumnar Spinal Devices Team

DHT6B: Division of Spinal Devices

OHT6: Office of Orthopedic Devices





Regulatory Review




Class II – Moderate Risk Devices

Emphasis is on the 5 points in Section V.A of FDA’s Sterile Devices Guidance, but comprehensive testing must be completed and will be reviewed in-depth upon inspection.

Class III – High Risk Devices

We comprehensively evaluate all test data upon submission.


In both instances, **all required testing must be completed** and documented (and available for review) for each device type. **What differs is WHEN it is reviewed.** And even that may vary depending upon device type (e.g., existence of a “device specific guidance”) or on an “as needed” basis.



OBJECTIVES: MEDICAL DEVICE STABILITY

1. To understand packaging validation methods for terminally sterilized single-use medical devices:
 - a. Package STABILITY – aging and shelf-life testing
 - b. Package PERFORMANCE – distribution and integrity testing
2. To understand the use-life/reuse-life/service-life options for reusable medical devices, and how these are established

Product Stability and Performance are also evaluated



PACKAGING

STERILE BARRIER SYSTEMS



3.23

sterile barrier system — **SBS**

minimum package that minimizes the risk of ingress of microorganisms and allows aseptic presentation of the sterile contents at the point of use

[SOURCE: ISO 11139:2018, 3.272]

From a microbiology perspective, the sterile barrier system (SBS) should be designed to **assure adequate sterilant penetration, as well as **maintenance of sterility**; from the point of sterilization during manufacture, to the time and place of medical device use.**

- FDA recommends that package “**performance**” testing be designed and implemented to assure that the packaged product can **withstand the rigors of real world, worst-case shipping** and handling.
- FDA recommends that package “**stability**” testing be conducted to assure that the packaging will **maintain product sterility** for the duration of the stated expiration date.



FDA's 2016 Sterile Devices Guidance



Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile

Guidance for Industry and Food and Drug Administration Staff

Document issued on January 21, 2016.

The draft of this document was issued on December 12, 2008.

As of March 21, 2016, this document supersedes "Updated 510(k) Sterility Review Guidance K90-1" issued August 30, 2002.

This guidance has been updated March 16, 2016 to correct an inadvertent editorial change regarding reporting of endotoxin limits.

For questions about this document regarding CDRH-regulated devices, contact the Infection Control Devices Branch (INCB) at 301-796-5580.

For questions about this document regarding CBER-regulated devices, contact CBER's Office of Communication, Outreach, and Development (OCOD) at 1-800-835-4709 or 240-402-8010.



U.S. Department of Health and Human Services
Food and Drug Administration
Center for Devices and Radiological Health
Center for Biologics Evaluation and Research




TABLE OF CONTENTS

STERILE DEVICES GUIDANCE



I. INTRODUCTION

II. BACKGROUND

III. SCOPE


- What is included; what is excluded

IV. STERILIZATION METHOD CATEGORIES

- Definitions (Established A, B, and Novel)
- Examples follow each definition

V. INFORMATION TO BE INCLUDED IN SUBMISSIONS

1. Sterilization Method
2. Validation Method
3. Sterility Assurance Level (SAL)
4. Pyrogenicity
5. Packaging




V. Sterilization Information for Devices Labeled Sterile



Sponsors should ensure the submission includes:

1. **Sterilization method description** per parts “a” to “f” (to include content such as chamber description, dose, residuals, as applicable)
2. **Validation method**, and relevant standards, or a comprehensive description of the process and validation protocol.
3. **Sterility assurance level (SAL)** of 10^{-6} for devices labeled as sterile, 10^{-3} for devices that only contact intact skin.
4. **Pyrogenicity Claim**, if applicable:
a description of the method, batch testing or sampling plan confirmation, the chosen testing limit and its justification, in endotoxin units/device.
5. **A description of the packaging** (sterile barrier system) and how it will maintain the device’s sterility, and a **description of the package test methods**, but **not package test data**.*

* Some device submissions should provide packaging data (e.g., prefilled saline syringes). This depends on device type, so know your particular device types and review practices.




V. Sterilization Information for Devices Labeled Sterile



Sponsors should ensure the submission includes:

5. A **description of the packaging** (sterile barrier system) and how it will maintain the device's sterility, and a **description of the package test methods**, but not package test data.¹³

¹³ FDA recommends that package test methods include **simulated distribution and associated package integrity**, as well as **simulated (and/or real-time) aging and associated seal strength testing**, to validate package integrity and shelf-life claims. Please refer to the current, FDA-recognized version of the AAMI/ANSI/**ISO 11607**-series of consensus standards.




V. Sterilization Information for Devices Labeled Sterile



Sponsors should ensure the submission includes:

5. A description of the packaging (sterile barrier system) and how it will maintain the device's sterility, and **the package test methods**, but not package test data.¹³

¹³ FDA recommends that package test methods include **simulated distribution and associated package integrity**, as well as **simulated (and/or real-time) aging and associated seal strength testing**, to validate package integrity and shelf-life claims. Please refer to the current, FDA-recognized version of the **AAMI/ANSI/ISO 11607**-series of consensus standards.



V. Sterilization Information for Devices Labeled Sterile




Sponsors should ensure the submission includes:

5. A **description of the packaging** (sterile barrier system) and how it will **maintain the device's sterility**, and **the package test methods**, but not package test data.

A simple summary of the testing design is sufficient:

- **simulated shipping** followed by **package integrity** testing
and
- **aging** followed by **seal strength** testing.

Or a statement of conformity to the AAMI/ANSI/ISO 11607-series of consensus standards would suffice.



V. Sterilization Information for Devices Labeled Sterile



Sponsors should ensure the submission includes:

5. A description of the packaging (sterile barrier system) and how it will maintain the device's sterility, and **the package test methods**, but not package test data.

A more comprehensive response might look like:

PERFORMANCE:

Simulated distribution (e.g., ASTM D4169 “*Standard Practice for Performance Testing of Shipping Containers and Systems*”)

followed by

Package integrity (e.g., ASTM F1929 “*Standard Test Method for Detecting Seal Leaks in Porous Medical Packaging by Dye Penetration*”)

plus

STABILITY:


Simulated aging (ASTM F1980 “*Standard Guide for Accelerated Aging of Sterile Medical Device Packages*”) or (and/or real-time) aging

followed by

Seal strength testing (e.g., ASTM F88 “*Standard Test Method for Seal Strength of Flexible Barrier Materials*”)

DOUBLE STERILE BARRIER SYSTEM — EXAMPLE VALIDATION FLOWCHART

This is an example of a flowchart. It represents a hypothetical series of simulations and subsequent tests, intended to provide a high level of assurance that the packaging will demonstrate adequate stability, and the packaged product will be able to withstand real world, worst-case shipping and handling, without package failure or sterile barrier breach. The details of this test schedule may or may not be appropriate for other products, as test procedures should be developed on a case-by-case basis. In general, the Agency considers breach of the sterile barrier system to more likely be event related, than time related.



* See applicable FDA recognized consensus standards, available at <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm>.

Examples: ISO 11607: Packaging for terminally sterilized medical devices, Parts 1 and 2; ASTM D4169 Performance Testing of Shipping Containers and Systems; ASTM F1980 (Accelerated Aging); ASTM F1929 (Dye Penetration Test); ASTM F88 (Seal Strength); ASTM F1886 (Visual Inspection).

** All test methods should be validated, use statistically significant sample sizes (95% Confidence and 95% Reliability is recommended), and include a predetermined, scientifically justified test endpoint.



PACKAGING



INTERNATIONAL STANDARD **ISO 11607-1**

Second edition
2019-02

Packaging for terminally sterilized medical devices —

Part 1:
Requirements for materials, sterile barrier systems and packaging systems

*Emballages des dispositifs médicaux stérilisés au stade terminal —
Partie 1: Exigences relatives aux matériaux, aux systèmes de barrière stérile et aux systèmes d'emballage*



Reference number
ISO 11607-1:2019(E)

© ISO 2019

INTERNATIONAL STANDARD **ISO 11607-2**

Second edition
2019-02

Packaging for terminally sterilized medical devices —

Part 2:
Validation requirements for forming, sealing and assembly processes

*Emballages des dispositifs médicaux stérilisés au stade terminal —
Partie 2: Exigences de validation pour les procédés de formage, scellage et assemblage*



Reference number
ISO 11607-2:2019(E)

© ISO 2019



PACKAGING



INTERNATIONAL STANDARD **ISO 11607-1**

Second edition
2019-02

Packaging for terminally sterilized medical devices —

Part 1:
Requirements for materials, sterile barrier systems and packaging systems

*Emballages des dispositifs médicaux stérilisés au stade terminal —
Partie 1: Exigences relatives aux matériaux, aux systèmes de barrière stérile et aux systèmes d'emballage*



Reference number
ISO 11607-1:2019(E)

© ISO 2019

1 Scope


This document specifies [requirements and test methods for materials, preformed sterile barrier systems, sterile barrier systems and packaging systems](#) that are intended to maintain sterility of terminally sterilized medical devices until the point of use.

It is [applicable to industry, to health care facilities](#), and to wherever medical devices are placed in sterile barrier systems and sterilized.

It does not cover all requirements for sterile barrier systems and packaging systems for medical devices that are manufactured aseptically. Additional requirements can be necessary for drug/device combinations.

It does not describe a quality assurance system for control of all stages of manufacture.

It does not apply to packaging materials and/or systems used to contain a contaminated medical device during transportation of the item to the site of reprocessing or disposal.



PACKAGING




INTERNATIONAL STANDARD **ISO 11607-2**

Second edition
2019-02

Packaging for terminally sterilized medical devices —
Part 2:
Validation requirements for forming, sealing and assembly processes

*Emballages des dispositifs médicaux stérilisés au stade terminal —
Partie 2: Exigences de validation pour les procédés de formage, scellage et assemblage*

Reference number
ISO 11607-2:2019(E)

 © ISO 2019

1 Scope

This document specifies requirements for the development and validation of processes for packaging medical devices that are terminally sterilized. These processes include forming, sealing and assembly of preformed sterile barrier systems, sterile barrier systems and packaging systems.

It is applicable to industry, to health care facilities, and to wherever medical devices are packaged and sterilized.

It does not cover all requirements for packaging medical devices that are manufactured aseptically. Additional requirements can be necessary for drug/device combinations.



PACKAGING - Terminology



aseptic presentation

transfer of sterile contents from its sterile barrier system using conditions and procedures that minimize the risk of microbial contamination

microbial barrier


property of a sterile barrier system to minimize the risk of ingress of microorganisms

packaging system

combination of a sterile barrier system and protective packaging


preformed sterile barrier system

sterile barrier system (3.23) that is supplied partially assembled for filling and final closure or sealing
EXAMPLE Pouches, bags and open reusable containers (3.17).



protective packaging

configuration of materials designed to prevent damage to the sterile barrier system and its contents from the time of their assembly until the point of use



PACKAGING - Terminology



process parameter

specified value for a *process variable* ([3.16](#))

Note 1 to entry: The [specification for a process](#) includes the process parameters and their tolerances.

seal integrity

<packaging> [characteristics of a seal to minimize the ingress of microorganisms](#)

seal strength

[mechanical capacity of the seal to withstand force](#)

sterile barrier system

SBS


minimum package that [minimizes the risk of ingress of microorganisms and allows aseptic presentation](#) of the sterile contents at the point of use

terminal sterilization

process whereby a product is [sterilized within its sterile barrier system](#)

DOUBLE STERILE BARRIER SYSTEM — EXAMPLE VALIDATION FLOWCHART

This is an example of a flowchart. It represents a hypothetical series of simulations and subsequent tests, intended to provide a high level of assurance that the packaging will demonstrate adequate stability, and the packaged product will be able to withstand real world, worst-case shipping and handling, without package failure or sterile barrier breach. The details of this test schedule may or may not be appropriate for other products, as test procedures should be developed on a case-by-case basis. In general, the Agency considers breach of the sterile barrier system to more likely be event related, than time related.



* See applicable FDA recognized consensus standards, available at <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm>.

Examples: ISO 11607: Packaging for terminally sterilized medical devices, Parts 1 and 2; ASTM D4169 Performance Testing of Shipping Containers and Systems; ASTM F1980 (Accelerated Aging); ASTM F1929 (Dye Penetration Test); ASTM F88 (Seal Strength); ASTM F1886 (Visual Inspection).

** All test methods should be validated, use statistically significant sample sizes (95% Confidence and 95% Reliability is recommended), and include a predetermined, scientifically justified test endpoint.



Standardized test methods to demonstrate

B.1 General

The following documents contain provisions that may be used to demonstrate conformity with provisions of this document. When using test methods and procedures listed in Table B.1, it is important to note the date of issue of these documents. Specific requirements for the use of test methods are found in 4.4.

The criteria for inclusion of test methods and procedures given in Table B.1 are that they shall be nominated for inclusion and commercially available from a standards development organization, trade association or national standards body. Consequently, the Bibliography contains additional test methods that were published in the literature. This annex is not intended to be all-inclusive and the development of new test methods is known to be underway at the time of publication.

B.2 Packaging materials and preformed sterile barrier systems

Attribute/Characteristics	Reference
Accelerated aging	ASTM F1980 EN 868-8
Air permeance	ISO 5636-3 ISO 5636-5 JIS P-8117

© ISO 2019 - All rights reserved
© AAMI 2019 ANSI/AAMI/ISO

B.1 General

The following documents contain provisions that may be used to demonstrate conformity with provisions of this document. When using test methods and procedures listed in Table B.1, it is important to note the date of issue of these documents. Specific requirements for the use of test methods are found in 4.4.

The criteria for inclusion of test methods and procedures given in Table B.1 are that they shall be nominated for inclusion and commercially available from a standards development organization, trade association or national standards body. Consequently, the Bibliography contains additional test methods that were published in the literature. This annex is not intended to be all-inclusive and the development of new test methods is known to be underway at the time of publication.

B.2 Packaging materials and preformed sterile barrier systems

Table B.1—Test methods and their status

Attribute/Characteristics	Reference	Title of reference	Test method has statement of precision and/or bias, repeatability and reproducibility	Test method only has statement of precision and/or bias	Guidance, Standard Practice
Accelerated aging	ASTM F1980	Standard guide for accelerated aging of sterile barrier systems for medical devices	NA ^a	NA	Yes
	EN 868-8	Packaging for terminally sterilized medical devices—Part 8: Re-usable sterilization containers for steam sterilizers conforming to EN 285 — Requirements and test methods	NA	NA	Yes
Air permeance	ISO 5636-3	Paper and board—Determination of air permeance (medium range)—Part 3: Bendtsen method	No	No	NA
	ISO 5636-5	Paper and board—Determination of air permeance and air resistance (medium range)—Part 5: Gurley method	No	No	NA
	JIS P-8117	Paper and board—Determination of air permeance and air resistance (medium range)—Gurley method	Yes	—	NA

Test method only has statement of precision and/or bias	Guidance, Standard Practice
—	NA
Yes	NA
—	NA
—	NA
No	NA
No	NA
No	NA
—	NA
—	NA
NA	Yes
NA	Yes
—	NA
—	NA
—	NA
—	NA
—	NA

© ISO 2019 - All rights reserved
ANSI/AAMI/ISO 11607-1:2019



ISO 16775 – PACKAGING – GUIDANCE ON 11607




TECHNICAL SPECIFICATION

ISO/TS
16775

Second edition
2021-11

**Packaging for terminally sterilized
medical devices — Guidance on the
application of ISO 11607-1 and ISO
11607-2**

*Emballages des dispositifs médicaux stérilisés au stade terminal —
Lignes directrices relatives à l'application de l'ISO 11607-1 et l'ISO
11607-2*

Reference number
ISO/TS 16775:2021(E)

© ISO 2021



PACKAGING



ISO/TS 16775:2021(E)

Contents		Page
Foreword		vii
Introduction		viii
1	Scope	1
2	Normative references	1
3	Terms and definitions	1
4	Guidance on Clauses 1-4 of ISO 11607-1:2019 and ISO 11607-2:2019	2
4.1	Scope (ISO 11607-1:2019, Clause 1 and ISO 11607-2:2019, Clause 1)	2
4.1.1	Intent	2
4.1.2	Guidance	2
4.2	Normative references (ISO 11607-1:2019, Clause 2 and ISO 11607-2:2019, Clause 2)	3
4.2.1	Intent	3
4.2.2	Guidance	3
4.3	Terms and definitions (ISO 11607-1:2019, Clause 3 and ISO 11607-2:2019, Clause 3)	4
4.3.1	Intent	4
4.3.2	Guidance	4
4.4	Quality and risk management (ISO 11607-1:2019, 4.1, 4.2 and ISO 11607-2:2019, 4.1, 4.2)	4
4.4.1	Intent	4
4.4.2	Guidance	4
4.5	Sampling (ISO 11607-1:2019, 4.3 and ISO 11607-2:2019, 4.3)	6
4.5.1	Intent	6
4.5.2	Guidance	6
4.6	Test methods (ISO 11607-1:2019, 4.4 and ISO 11607-2:2019, 4.4)	7
4.6.1	Intent	7
4.6.2	Guidance	7
4.7	Documentation (ISO 11607-1:2019, 4.5 and ISO 11607-2:2019, 4.5)	9
4.7.1	Intent	9
4.7.2	Guidance	9
5	Guidance on Clauses 5-11 of ISO 11607-1:2019	10
5.1	General requirements for materials, preformed sterile barrier systems and sterile barrier systems (ISO 11607-1:2019, 5.1.1 and 5.1.2)	10
5.1.1	Intent	10
5.1.2	Guidance	10
5.2	Conditions for production and handling (ISO 11607-1:2019, 5.1.3 and 5.1.4)	10
5.2.1	Intent	10
5.2.2	Guidance	10
5.3	Source, history and traceability of materials (ISO 11607-1:2019, 5.1.5)	11
5.3.1	Intent	11
5.3.2	Guidance	11
5.4	Properties to be evaluated (ISO 11607-1:2019, 5.1.6)	12
5.4.1	Intent	12
5.4.2	Guidance	12
5.5	<u>General performance requirements for materials</u> (ISO 11607-1:2019, 5.1.7 and 5.1.8)	12
5.5.1	Intent	12
5.5.2	Guidance	13
5.6	<u>Additional requirements for sterile barrier systems and preformed sterile barrier systems</u> (ISO 11607-1:2019, 5.1.9)	16
5.6.1	Intent	16
5.6.2	Guidance	16
5.7	Reusable sterile barrier systems (ISO 11607-1:2019, 5.1.10, 5.1.11 and 5.1.12)	17
5.7.1	Intent	17

ISO/TS 16775:2021(E)

5.7.2	Guidance	17
5.8	Microbial barrier properties (ISO 11607-1:2019, 5.2)	17
5.8.1	Intent	17
5.8.2	Guidance	17
5.9	<u>Compatibility with the sterilization process</u> (ISO 11607-1:2019, 5.3)	18
5.9.1	Intent	18
5.9.2	Guidance	18
5.10	Labelling system (ISO 11607-1:2019, 5.4)	19
5.10.1	Intent	19
5.10.2	Guidance	19
5.11	Storage and transport of materials and preformed sterile barrier systems (ISO 11607-1:2019, 5.5)	21
5.11.1	Intent	21
5.11.2	Guidance	21
5.12	Design and development (ISO 11607-1:2019, 6.1.1)	22
5.12.1	Intent	22
5.12.2	Guidance	22
5.13	Aseptic presentation (ISO 11607-1:2019, 6.1.2)	23
5.13.1	Intent	23
5.13.2	Guidance	23
5.14	Physical protection (ISO 11607-1:2019, 6.1.3 and 6.1.4)	24
5.14.1	Intent	24
5.14.2	Guidance	24
5.15	Sterilization compatibility (ISO 11607-1:2019, 6.1.5)	25
5.15.1	Intent	25
5.15.2	Guidance	25
5.16	Maintenance of Sterility (ISO 11607-1:2019, 6.1.6 and 6.1.7)	25
5.16.1	Intent	25
5.16.2	Guidance	25
5.17	Requirements for multi-layer packaging (ISO 11607-1:2019, 6.1.8)	26
5.17.1	Intent	26
5.17.2	Guidance	26
5.18	<u>Packaging families</u> (ISO 11607-1:2019, 6.1.9)	27
5.18.1	Intent	27
5.18.2	Guidance	27
5.19	Design process (ISO 11607-1:2019, 6.2.1)	28
5.19.1	Intent	28
5.19.2	Guidance	29
5.20	Design inputs (ISO 11607-1:2019, 6.2.2 and 6.2.3)	29
5.20.1	Intent	29
5.20.2	Guidance	29
5.21	Sterile fluid path (ISO 11607-1:2019, 6.2.4, 6.2.5)	31
5.21.1	Intent	31
5.21.2	Guidance	31
5.22	Usability evaluation for aseptic presentation (ISO 11607-1:2019, 7.1, 7.2 and 7.3)	32
5.22.1	Intent	32
5.22.2	Guidance	32
5.23	Leveraging usability evaluations (ISO 11607-1:2019, 7.4)	33
5.23.1	Intent	33
5.23.2	Guidance	33
5.24	Usability evaluation failures (ISO 11607-1:2019, 7.5)	33
5.24.1	Intent	33
5.24.2	Guidance	33
5.24.3	Guidance on formative and summative studies	34
5.25	Packaging system performance and stability (ISO 11607-1:2019, 8.1)	35
5.25.1	Intent	35
5.25.2	Guidance	35
5.26	Packaging system performance testing (ISO 11607-1:2019, 8.2)	37

PACKAGING




ISO/TS 16775:2021(E)

5.26.1	Intent	37
5.26.2	Guidance	37
5.27	Stability testing (ISO 11607-1:2019, 8.3)	38
5.27.1	Intent	38
5.27.2	Guidance	38
5.28	Packaging system validation and changes (ISO 11607-1:2019, 9.1)	40
5.28.1	Intent	40
5.28.2	Guidance	40
5.29	Change control (ISO 11607-1:2019, 9.2)	40
5.29.1	Intent	40
5.29.2	Guidance	40
5.30	Revalidations (ISO 11607-1:2019, 9.3, 9.4, and 9.5)	40
5.30.1	Intent	40
5.30.2	Guidance	40
5.31	Inspection immediately prior to aseptic presentation (ISO 11607-1:2019, Clause 10)	41
5.31.1	Intent	41
5.31.2	Guidance	41
5.32	Information to be provided (ISO 11607-1:2019, Clause 11)	41
5.32.1	Intent	41
5.32.2	Guidance	41
6	Guidance on Clauses 5-8 of ISO 11607-2:2019	42
6.1	General Clauses 1-4 of ISO 11607-2:2019	42
6.2	Validation of packaging processes - general requirements (ISO 11607-2:2019, 5.1.1 and 5.1.2)	42
6.2.1	Intent	42
6.2.2	Guidance	42
6.3	Process specification (ISO 11607-2:2019, 5.1.3)	43
6.3.1	Intent	43
6.3.2	Guidance	43
6.4	<u>Process validation of packaging families</u> (ISO 11607-2:2019, 5.1.4)	43
6.4.1	Intent	43
6.4.2	Guidance	43
6.5	Installation qualification (ISO 11607-2:2019, 5.2)	44
6.5.1	Intent	44
6.5.2	Guidance	45
6.6	Operational qualification (ISO 11607-2:2019, 5.3)	45
6.6.1	Intent	45
6.6.2	Guidance	46
6.7	Performance qualification (ISO 11607-2:2019, 5.4)	46
6.7.1	Intent	46
6.7.2	Guidance	46
6.8	Formal approval of the process validation (ISO 11607-2:2019, 5.5)	47
6.8.1	Intent	47
6.8.2	Guidance	47
6.9	Process control and monitoring (ISO 11607-2:2019, 5.6)	48
6.9.1	Intent	48
6.9.2	Guidance	48
6.10	<u>Process changes and revalidation</u> (ISO 11607-2:2019, 5.7)	48
6.10.1	Intent	48
6.10.2	Guidance	48
6.11	Assembly (ISO 11607-2:2019, Clause 6)	49
6.11.1	Intent	49
6.11.2	Guidance	49
6.12	Use of reusable sterile barrier systems (ISO 11607-2:2019, Clause 7)	51
6.12.1	Intent	51
6.12.2	Guidance	51
6.13	Sterile fluid path packaging (ISO 11607-2:2019, Clause 8)	51
6.13.1	Intent	51

ISO/TS 16775:2021(E)

6.13.2	Guidance	51
Annex A (informative) Design and development for packaging systems - guidance for industry		52
Annex B (informative) Guidance on the application of the ISO 11607 series in healthcare facilities		60
Annex C (informative) Risk analysis tools — Guidance for industry and healthcare facilities		91
Annex D (informative) Considerations for sampling plans - Guidance for healthcare facilities		93
Annex E (informative) <u>Guidance on establishing process parameters - guidance for industry</u>		95
Annex F (informative) <u>Sterilization considerations - Guidance for industry and healthcare facilities</u>		101
Annex G (informative) Use of contract packagers - Guidance for industry and healthcare facilities		108
Annex H (informative) Example of a handling, distribution and storage checklist - Guidance for healthcare facilities for selecting a sterile barrier system		109
Annex I (informative) <u>Investigating failure - Guidance for industry and healthcare facilities</u>		112
Annex J (informative) Validation summary - Guidance for healthcare facilities		116
Annex K (informative) Validation for wrapping process — Guidance for healthcare facilities		118
Annex L (informative) Validation for reusable container process - Guidance for healthcare facilities		124
Annex M (informative) Validation for heat sealing process for preformed sterile barrier systems (PSBS) - Guidance for healthcare facilities		130
Annex N (informative) Evaluation of sterile packaging by end users — Guidance for healthcare facilities		138
Bibliography		139



V. Sterilization Information for Devices Labeled Sterile


Sponsors should ensure the submission includes:

5. A **description of the packaging** (sterile barrier system) and how it will maintain the device's sterility, and **the package test methods**, but **not package test data**.


Examples - Package Materials and Compatibility.

Allows for sterilant penetration & sterility maintenance.

- EO: Breathable materials –
 - Tyvek/Mylar combination, or Tyvek/PETG tray
- Steam: must allow steam penetration
 - Paper/plastic (possibly, for low temps, Tyvek/film).
- Radiation: can be non-breathable.
 - foil, Mylar, film
- Dry Heat: Varies - must allow for transfer of heat.



PACKAGING MATERIALS – EXAMPLE





PACKAGING

Miscellaneous P and 1059B Trans

Property	Comparable Test Method	Units	Current Type
Microbial Barrier	ASTM F1608 ASTM F2638	LRV % pMax	
Bendtsen Air Permeability	ISO 5636-3	mL/min	
Moisture Vapor Transmission Rate	TAPPI T523 ¹	g/m ² /24 hr	
Hydrostatic Head	AATCC TM 127 EN 20811 ²	cm H ₂ O	
Tensile Strength, MD	ASTM D5035 ³ EN ISO 1924-2 ³	N/2.54 cm	
Tensile Strength, CD	ASTM D5035 ³ EN ISO 1924-2 ³	N/2.54 cm	
Elongation, MD	ASTM D5035 ³ EN ISO 1924-2 ³	%	
Elongation, CD	ASTM D5035 ³ EN ISO 1924-2 ³	%	
Elmendorf Tear, MD	ASTM D1424 EN 21974	N	
Elmendorf Tear, CD	ASTM D1424 EN 21974	N	
Mullen Burst	ASTM D774 ISO 2758	kPa	
Spencer Puncture	ASTM D3420 ⁴	J/m ²	


Opacity	TAPPI T425 ISO 2471 ⁵	%	
Thickness (Individual)*	ASTM D1777 ⁶ EN 20534 ⁷ EN ISO 534	µm	

NOTES: 1079B and 1059B Transition Protocol typical values represent values based on roll averages, except for thickness (individual), with sample pooled individual data points from multiple rolls. Miscellaneous product drift. Customers must conduct their own tests to ensure suitability. Any downstream operations, such as coatings applied by sterile packaging, may affect performance. *Thickness variability target is equal to, or less than, incumbent product. MD = machine direction; CD = cross direction; LRV = log reduction.

This information is based upon technical data that DuPont believes to be accurate. It is intended for use by persons having technical skill for evaluation and NO WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE. This information is not intended as a license to operate under a patent. Copyright © 2014 DuPont. All rights reserved. The DuPont Oval Logo, DuPont

PROPERTIES

Property	Comparable Test Method	Units
Microbial Barrier	ASTM F1608 ASTM F2638	LRV % pMax
Bendtsen Air Permeability	ISO 5636-3	mL/min
Moisture Vapor Transmission Rate	TAPPI T523 ¹	g/m ² /24 hr
Hydrostatic Head	AATCC TM 127 EN 20811 ²	cm H ₂ O
Tensile Strength, MD	ASTM D5035 ³ EN ISO 1924-2 ³	N/2.54 cm
Tensile Strength, CD	ASTM D5035 ³ EN ISO 1924-2 ³	N/2.54 cm
Elongation, MD	ASTM D5035 ³ EN ISO 1924-2 ³	%
Elongation, CD	ASTM D5035 ³ EN ISO 1924-2 ³	%
Elmendorf Tear, MD	ASTM D1424 EN 21974	N
Elmendorf Tear, CD	ASTM D1424 EN 21974	N
Mullen Burst	ASTM D774 ISO 2758	kPa
Spencer Puncture	ASTM D3420 ⁴	J/m ²



Property	1059B Transition Protocol Typical Value
Microbial Barrier	>4
Bendtsen Air Permeability	<0.5
Moisture Vapor Transmission Rate	557
Hydrostatic Head	>1600
Tensile Strength, MD	157
Tensile Strength, CD	190
Elongation, MD	185
Elongation, CD	19
Elmendorf Tear, MD	23
Elmendorf Tear, CD	3.0
Mullen Burst	3.8
Spencer Puncture	1034
Opacity	7746
Thickness (Individual)*	92
	178

% RH.
in.
in. gage length.
8-mm) probe.
king standards, area and illumination.
ter presser foot.
4.5 psi (100 kPa).

connection with this information.
ED, INCLUDING WITHOUT LIMITATIONS,



PACKAGING – SIMULATIONS AND TESTING



This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

 Designation: D4169 – 22

Standard Practice for Performance Testing of Shipping Containers and Systems¹

This standard original adopted superscript epsilon (ε) This standard

1. Scope

1.1 This practice provides a laboratory, the ability to simulate the distribution environment of a test plan containing hazardous elements encountered during shipping. This practice is not intended to be used for existing preshipment testing.

1.2 Consider the use of preshipment testing for packages for single parcels.

1.3 The suitability of materials has not been determined.


1.4 The values stated are as standard. The values given in parentheses are conversions to SI units that are not considered for use.

1.5 *This standard does not address safety concerns, if any, that may be the responsibility of the user. Guidance for appropriate safety, health, and environmental applicability of this standard is given in the annex.*

1.6 *This international standard is in accordance with international standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT).*

¹ This practice is under the jurisdiction of ASTM International and is the direct responsibility of ASTM International. Current edition approved January 1, 2022. Last previous edition approved in 2004. 10.1520/D4169-22.

This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

 Designation: F1980 – 21

Standard Guide for Accelerated Aging of Sterile Barrier Systems and Medical Devices¹

This standard original adopted superscript epsilon (ε)

1. Scope

1.1 This guide provides a procedure for accelerated aging protocols for sterile barrier systems (SBS), as defined in the glossary, and the physical properties of the materials. Guidance for the use of this guide may also be used for other medical devices.


1.2 Information on the use of accelerated aging studies are available in the glossary.

1.3 The accelerated aging systems as a whole with the system material and components be required for new product development. Evaluation is not addressed.

1.4 Real-time aging studies are not addressed; however, it is recommended that the same methods of accelerated aging be used for the requirement of accelerated aging.

1.5 Methods used for accelerated aging are discussed in the glossary.

This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

 Designation: F1929 – 15

Standard Test Method for Detecting Seal Leaks in Porous Medical Packaging by Dye Penetration¹


This standard original adopted superscript epsilon (ε)

1. Scope

1.1 This test method will detect and locate seal leaks in porous material formed by a 50 µm or larger pore size. A dye penetrant is used to detect the leak. A dye penetrant is used to detect the leak.

1.2 Three dye application methods are discussed: injection, immersion, and spray.

This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.


 Designation: F88/F88M – 21

Standard Test Method for Seal Strength of Flexible Barrier Materials¹

This standard is issued under the fixed designation F88/F88M; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon (ε) indicates an editorial change since the last revision or reapproval.

DOUBLE STERILE BARRIER SYSTEM — EXAMPLE VALIDATION FLOWCHART


This is an example of a flowchart. It represents a hypothetical series of simulations and subsequent tests, intended to provide a high level of assurance that the packaging will demonstrate adequate stability, and the packaged product will be able to withstand real world, worst-case shipping and handling, without package failure or sterile barrier breach. The details of this test schedule may or may not be appropriate for other products, as test procedures should be developed on a case-by-case basis. In general, the Agency considers breach of the sterile barrier system to more likely be event related, than time related.



* See applicable FDA recognized consensus standards, available at <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm>.

Examples: ISO 11607: Packaging for terminally sterilized medical devices, Parts 1 and 2; ASTM D4169 Performance Testing of Shipping Containers and Systems; ASTM F1980 (Accelerated Aging); ASTM F1929 (Dye Penetration Test); ASTM F88 (Seal Strength); ASTM F1886 (Visual Inspection).


** All test methods should be validated, use statistically significant sample sizes (95% Confidence and 95% Reliability is recommended), and include a predetermined, scientifically justified test endpoint.



PACKAGING and ACCELERATED AGING



- ASTM F1980-21: “Standard Guide for Accelerated Aging of Sterile Barrier Systems for Medical Devices”
- “SHELF LIFE OF MEDICAL DEVICES” - FDA 1991, Guidance Document
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/shelf-life-medical-devices>
- “General Aging Theory and Simplified Protocol for Accelerated Aging of Medical Devices” - <https://www.mddionline.com/design-engineering/general-aging-theory-and-simplified-protocol-accelerated-aging-medical-devices>
- ASTM F1980: Accelerated Aging Time and Temperature
- <https://www.youtube.com/watch?v=0H-ePF0KxLs>



PACKAGING and ACCELERATED AGING



Shelf Life of Medical Devices - FDA Guidance


As a rule of thumb, every 10°C increase for the tested temperature above normal storage temperature will enhance the expiration date by a factor of two.

- <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/shelf-life-medical-devices>

Accelerated Aging Testing

The Arrhenius equation indicates that a +10°C increase in temperature doubles the rate (known as a Q_{10} factor of 2) of chemical reaction. This is the most popular and conservative method of calculating Accelerated Aging.

- <https://www.westpak.com/industry-solutions/medical-device/accelerated-aging/>



PACKAGING and ACCELERATED AGING



Shelf Life of Medical Devices - FDA Guidance

“Accelerated studies, combined with basic stability information on the components, drug products, and container-closure system, may be used to support tentative expiration dates provided full shelf life studies are not available and are being conducted.”


Procedure for Testing Shelf Life

A written procedure for establishing and monitoring shelf life of medical devices should include the following:

5. Accelerated Aging Parameters, including information that validates the accelerated system. The results need to be supported by real time testing of shelf life samples to confirm the tentative shelf life data collected from the accelerated tests.

ISO 11607-1

8.3.3 Stability testing, using accelerated aging protocols, shall be regarded as sufficient evidence for claimed expiry dates until data from real-time aging studies are available.



LIMITATIONS – Temperature and Materials

ASTM F1980: Standard for Accelerated Aging of Sterile Barrier Systems and Medical Devices

What is the best temperature to use for an ASTM F1980 test?

The **ASTM F1980 standard suggests using an accelerated aging temperature below 60°C**. Aging your product at a greater temperature provides the **advantage** of a faster simulation of the aging interval, but this comes with **risks** for particular products and packaging materials. **Medical devices are often engineered with delicate materials that may drastically change when exposed to temperatures exceeding +60°C**.

- <https://www.westpak.com/test-standards/astm-f1980/#:~:text=What%20is%20the%20best%20temperature,temperature%20below%2060%C2%B0C>.

In general, all materials have different Q_{10} factors; but most of those used in packaging have a $Q_{10} = 2$.

General Aging Theory and Simplified Protocol for Accelerated Aging of Medical Devices

[Karl J. Hemmerich](#)

<https://www.mddionline.com/design-engineering/general-aging-theory-and-simplified-protocol-accelerated-aging-medical-devices>






Figure 1. Accelerated aging of polymers (time versus temperature), showing the time (in weeks) equivalent to 1 year of room-temperature aging when a polymer is heat-aged at a selected temperature (°C).

ACCELERATED AGING





ARRHENIUS EQUATION



Accelerated Aging Time = Desired Real Time divided by the Accelerated Aging Factor

$$365 \text{ Days} / \text{AAF} = Q_{10}^{[(T_{AA} - T_{RT})/10]}$$

AAF – Accelerated Aging Factor

Q_{10} – Factor depending on material type

T_{AA} – Accelerated Aging Temperature

T_{RT} – Storage Temperature

$$365 \text{ Days} / 2^{[(T_{AA} - T_{RT})/10]}$$


$$365 \text{ Days} / 2^{[(55^{\circ}\text{C} - 23^{\circ}\text{C})/10]}$$

$$365 \text{ Days} / 2^{[(32^{\circ}\text{C})/10]}$$

$$365 \text{ Days} / 2^{[3.2]}$$

$$365 \text{ Days} / 9.19$$

39.72 Days Accelerated = 1 Year Real Time



ARRHENIUS EQUATION



Accelerated Aging Time = Desired Real Time divided by the Accelerated Aging Factor

$$365 \text{ Days} / \text{AAF} = Q_{10}^{[(T_{AA} - T_{RT})/10]}$$

AAF – Accelerated Aging Factor

Q_{10} – Factor depending on material type

T_{AA} – Accelerated Aging Temperature

T_{RT} – Storage Temperature

$$365 \text{ Days} / 2^{[(T_{AA} - T_{RT})/10]}$$

$$365 \text{ Days} / 2^{[(50^{\circ}\text{C} - 23^{\circ}\text{C})/10]}$$

$$365 \text{ Days} / 2^{[(27^{\circ}\text{C})/10]}$$

$$365 \text{ Days} / 2^{[2.7]}$$

$$365 \text{ Days} / 6.5$$

56.15 Days Accelerated = 1 Year Real Time



ARRHENIUS EQUATION



Accelerated Aging Time = Desired Real Time divided by the Accelerated Aging Factor

$$365 \text{ Days} / \text{AAF} = Q_{10}^{[(T_{AA} - T_{RT})/10]}$$

AAF – Accelerated Aging Factor

Q_{10} – Factor depending on material type

T_{AA} – Accelerated Aging Temperature

T_{RT} – Storage Temperature

$$365 \text{ Days} / 2^{[(T_{AA} - T_{RT})/10]}$$

$$365 \text{ Days} / 2^{[(60^{\circ}\text{C} - 23^{\circ}\text{C})/10]}$$

$$365 \text{ Days} / 2^{[(37^{\circ}\text{C})/10]}$$

$$365 \text{ Days} / 2^{[3.7]}$$

$$365 \text{ Days} / 12.99$$

28.1 Days Accelerated = 1 Year Real Time



PACKAGING



This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

 Designation: D4169 – 22

Standard Practice for Performance Testing of Shipping Containers and Systems¹

This standard original adopted superscript epsilon (ε) indicates an editorial change since the last revision or reapproval.

This standard is under the jurisdiction of ASTM International, Committee F08 on Packaging and Shipping Containers, and is the direct responsibility of Subcommittee F08.02 on Performance Testing of Shipping Containers and Systems. Current edition approved January 10, 2022. Last previous edition 2016.

1. Scope

1.1 This practice provides a laboratory, the ability to simulate the distribution environment of shipping containers and systems to a test plan containing hazardous elements encountered during shipping. This practice is not intended to be used for existing preshipment testing.

1.2 Consider the use of shipping containers and packages for single parcels.

1.3 The suitability of materials has not been determined.


1.4 The values stated are as standard. The values given in parentheses are conversions to SI units and are not considered standard.

1.5 *This standard does not address safety concerns, if any, that may be associated with the use of this standard. It is the responsibility of the user to determine appropriate safety, health, and environmental protection measures and the applicability of this standard to their specific circumstances.*

1.6 *This international standard is in accordance with international standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT).*

¹ This practice is under the jurisdiction of ASTM International, Committee F08 on Packaging and Shipping Containers, and is the direct responsibility of Subcommittee F08.02 on Performance Testing of Shipping Containers and Systems. Current edition approved January 10, 2022. Last previous edition 2016.

This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

 Designation: F1980 – 21

Standard Guide for Accelerated Aging of Sterile Barrier Systems and Medical Devices¹

This standard original adopted superscript epsilon (ε) indicates an editorial change since the last revision or reapproval.

1. Scope

1.1 This guide provides accelerated aging protocols for the passage of time on a sterile barrier system (SBS), as defined in F1929, and the physical properties of the materials. Guidance for the use of this guide may also be used for other materials.


1.2 Information on the use of accelerated aging studies are available in F1929.

1.3 The accelerated aging systems as a whole with the system material and components be required for new product evaluation is not addressed.

1.4 Real-time aging studies are not addressed in this guide; however, it is recommended that they be performed to confirm the same methods of accelerated aging as the requirement of ASTM International.

1.5 Methods used for accelerated aging studies are not addressed in this guide.

This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

 Designation: F1929 – 15

Standard Test Method for Detecting Seal Leaks in Porous Medical Packaging by Dye Penetration¹


This standard original adopted superscript epsilon (ε) indicates an editorial change since the last revision or reapproval.

1. Scope

1.1 This test method will detect and locate seal leaks formed by a 50 µm pore size formed between a porous material. A dye penetrant is used to detect the edge to be tested for a specified time, and the dye is removed by penetration.


1.2 Three dye application methods: injection, etc.

This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

 Designation: F88/F88M – 21

Standard Test Method for Seal Strength of Flexible Barrier Materials¹

This standard is issued under the fixed designation F88/F88M; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon (ε) indicates an editorial change since the last revision or reapproval.



SEAL STRENGTH - ACCEPTANCE CRITERION




This should be scientifically justified:

- **There is no single standardized acceptance criterion.**
- **A common minimum value is 1 lb/inch, and values should be above this, but . . .**
 - **Too strong is problematic**
 - **Too weak is problematic**
- **Values below 1 lb/inch may be acceptable for smaller, lighter mass devices, if scientifically justified.**

DOUBLE STERILE BARRIER SYSTEM — EXAMPLE VALIDATION FLOWCHART


This is an example of a flowchart. It represents a hypothetical series of simulations and subsequent tests, intended to provide a high level of assurance that the packaging will demonstrate adequate stability, and the packaged product will be able to withstand real world, worst-case shipping and handling, without package failure or sterile barrier breach. The details of this test schedule may or may not be appropriate for other products, as test procedures should be developed on a case-by-case basis. In general, the Agency considers breach of the sterile barrier system to more likely be event related, than time related.



* See applicable FDA recognized consensus standards, available at <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm>.

Examples: ISO 11607: Packaging for terminally sterilized medical devices, Parts 1 and 2; ASTM D4169 Performance Testing of Shipping Containers and Systems; ASTM F1980 (Accelerated Aging); ASTM F1929 (Dye Penetration Test); ASTM F88 (Seal Strength); ASTM F1886 (Visual Inspection).

** All test methods should be validated, use statistically significant sample sizes (95% Confidence and 95% Reliability is recommended), and include a predetermined, scientifically justified test endpoint.



PACKAGING and ACCELERATED AGING




Shelf Life of Medical Devices - FDA Guidance

“Accelerated studies, combined with basic stability information on the components, drug products, and container-closure system, may be used to support tentative expiration dates provided full shelf life studies are not available and are being conducted.”

Procedure for Testing Shelf Life

A written procedure for establishing and monitoring shelf life of medical devices should include the following:

5. Accelerated Aging Parameters, including information that validates the accelerated system. The **results need to be supported by real time testing** of shelf life samples to confirm the tentative shelf life data collected from the accelerated tests.
6. **Simulation of Shipping and Handling Stresses Plan, including vibration tests, temperature extremes challenge, actual shipping and intentionally mishandling the device to determine the affect of unusual circumstances.**



PACKAGING – Draft Deficiency – Part 1



FDA recommends that package “performance” testing (shipping simulation followed by package integrity testing) and package “stability” testing (aging (real-time or accelerated aging followed by real-time) followed by seal strength testing), both be performed to demonstrate adequate functionality of the package design, as well as shelf life claims (please refer to an FDA-recognized standard such as the ANSI/AAMI/ISO 11607-series “*Packaging for terminally sterilized medical devices*” for additional information).

In general, FDA recommends:

- That package performance validation activities include conducting simulated shipping of packages followed by package integrity testing (e.g., dye penetration), and that package stability validation include aging of packages (real-time aging, or accelerated aging followed by confirmatory real-time aging) followed by seal strength testing. Furthermore, it is recommended that data from baseline (time “0”) testing on un-aged packages, as well as accelerated aging calculations, be documented in your records.

The Agency recommends the use of FDA-recognized consensus standards to simulate worst-case, real world shipping conditions by establishing a routing schedule and rigor of simulation (such as ASTM D4169, “*Standard Practice for Performance Testing of Shipping Containers and Systems*” and the associated Distribution Cycles and Assurance Levels defined within it), followed by package integrity testing.

Note: a searchable database of FDA-recognized consensus standards is available at:
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm>



PACKAGING



This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

ASTM INTERNATIONAL Designation: D4169 – 22

Standard Practice for Performance Testing of Shipping Containers and Systems¹

This standard is issued under the fixed designation D4169; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon (ϵ) indicates an editorial change since the last revision or reapproval.

This standard is under the jurisdiction of ASTM Committee F08 on Packaging and contains technical material for which international standards do not currently exist.

1. Scope

1.1 This practice provides a laboratory, the ability to test shipping containers and systems under distribution environment conditions. The test plan conditions and the hazard elements encountered during the distribution cycle. This practice is not intended to be used for existing preshipment testing.

1.2 Consider the use of shipping containers and systems for single packages for single packages.

1.3 The suitability of materials has not been determined.

1.4 The values stated are as standard. The values given in parentheses are conversions to SI units and are not considered standard.

1.5 *This standard does not cover safety concerns, if any, that may be associated with the use of the materials. It is the responsibility of the user to determine appropriate safety, health, and environmental concerns and to determine the applicability of this standard.*

1.6 *This international standard is in accordance with international standards established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.*

¹ This practice is under the jurisdiction of ASTM Committee F08 on Packaging and contains technical material for which international standards do not currently exist.

Current edition approved January 1, 2004. Last previous edition approved in 2004. 10.1520/D4169-22.

This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

ASTM INTERNATIONAL Designation: F1980 – 21

Standard Guide for Accelerated Aging of Sterile Barrier Systems¹

This standard is issued under the fixed designation F1980; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon (ϵ) indicates an editorial change since the last revision or reapproval.

1. Scope

1.1 This guide provides a procedure for accelerated aging protocols for the passage of time on a sterile barrier system (SBS), as defined in F1989, and the physical properties of the materials. Guidance for the use of this guide may also be used for other materials.

1.2 Information on the use of accelerated aging devices and sterile barrier systems are available in F1989.

1.3 The accelerated aging systems as a whole will be required for new systems and for evaluation is not addressed.

1.4 Real-time aging studies are not addressed in this guide; however, it is intended to be used to confirm the same methods of accelerated aging as the requirement of ASTM F1989.

1.5 Methods used for accelerated aging are:

This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

ASTM INTERNATIONAL Designation: F1929 – 15

Standard Test Method for Detecting Seal Leaks in Porous Medical Packaging by Dye Penetration¹

This standard is issued under the fixed designation F1929; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon (ϵ) indicates an editorial change since the last revision or reapproval.

1. Scope

1.1 This test method will detect and locate dye penetration formed by a 50 μ m pore size material. A dye penetration test is required for a specified time, and the dye penetration is not addressed.

1.2 Three dye application methods: injection, etc.

This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

ASTM INTERNATIONAL Designation: F88/F88M – 21

Standard Test Method for Seal Strength of Flexible Barrier Materials¹

This standard is issued under the fixed designation F88/F88M; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon (ϵ) indicates an editorial change since the last revision or reapproval.

3. Terminology

3.1 *Definitions*—General definitions for the packaging and distribution environments are found in Terminology D996.

3.2 *Definitions of Terms Specific to This Standard:*


3.2.1 *acceptance criteria, n*—the acceptable quality level that must be met after the shipping unit has been subjected to the test plan. See Section 7.

3.2.2 *assurance level, n*—the level of test intensity based on its probability of occurring in a typical distribution cycle.

3.2.2.1 *Discussion*—Level I is a high level of test intensity and has a low probability of occurrence. Level III is a low level of test intensity, but has a correspondingly high probability of occurrence. Level II is between these extremes. For Distribution Cycle 18 (DC-18), see MIL-STD-2073-1 for definitions of military levels of protection.

3.2.3 *coefficient of restitution, n*—the ratio of the rebound velocity to the impact velocity.

3.2.4 *distribution cycle (DC), n*—the sequential listing of the test schedules employed to simulate the hazard elements expected to occur for a specific routing of a shipping unit from production to consumption. See Table 1.



PACKAGING – Draft Deficiency – Part 2



- That **actual product or simulated product (that accurately mimics the device’s mass and surface geometry) be included in packages that undergo performance testing.** (In some instances, and if justified, it may be possible for package stability testing to be adequately designed and implemented without the inclusion of product (real or simulated) in the packaging.)
- That the number of samples used in package performance and package stability testing be large enough to provide for **statistically significant analysis with a high degree of reliability; in particular, 95% confidence and 95% reliability is recommended.** Accordingly, a minimum sample size of **60 is recommended for “attribute data” generated from performance tests such as dye penetration,** and a minimum sample size of **30 is recommended for “variable data” generated from stability tests such as seal strength.** The Agency further recommends that a full set of data be generated for both inner and outer sterile barriers for double sterile barrier systems.



SIMULATED SHIPPING AND HANDLING



TABLE 1 Distribution Cycles

DC	Distribution Cycle	Performance Test Schedule Sequence (see Section 9 for Test Schedule definition)						
		First	Second	Third	Fourth	Fifth	Sixth	Seventh
1	General Cycle—undefined distribution system							
2	Specially defined distribution system, user specified (see Appendix X2)							
3	Single package without pallet or skid, LTL motor freight							
4	Single package with pallet or skid, LTL motor freight							
5	Motor freight, TL, not unitized							
6	Motor freight, TL, or LTL—unitized							
7	Rail only, bulk loaded							



SIMULATED SHIPPING AND HANDLING



TABLE 1 Distribution Cycles

DC	Distribution Cycle	Performance Test Schedule Sequence (see Section 9 for Test Schedule definition)					Sixth	Seventh
		First	Second	Third	Fourth	Fifth		


13 Air (intercity) and motor freight (local, single package up to 150 lb (61.8 kg). Consider using Practice [D7386](#) for single parcel carrier shipments.

Schedule A Handling

Schedule C Vehicle Stacking

Schedule F Loose-Load Vibration


Other DC13 details omitted ...



PACKAGING – Draft Deficiency – Part 3

You have provided a description of your proposed packaging that **is designed to allow sterilant penetration**; however, it **is unclear whether or not the packaging has been adequately validated to maintain sterility** when subjected to the rigors of real-world shipping and handling, or to maintain sterility after aging.

- a. Please **clarify the proposed shelf life claim**/expiration date for the subject device, based on your validation activities.
- b. Please **identify all standards** used during the validation of your current packaging design.
- c. **[OPTION 1 – less rigorous, for 510(k)s]**
Please **provide a summary of your package performance and package stability validation activities**. This should indicate simulation and testing chronology, simulation methods (e.g., shipping, aging), test methods (e.g., dye penetration, seal strength), and confirmation that both inner and outer seals were tested, if your packaging consists of a double sterile barrier design.
- d. **[OPTION 2 – more rigorous, for PMAs]**
Please **provide a summary flowchart documenting your package performance and package stability validation activities**. This should indicate simulation and testing chronology, number of sterilization exposure cycles (if applicable), simulation methods (e.g., shipping, aging), test methods (e.g., dye penetration, seal strength), sample sizes and summary results, aging periods, identification of seal types tested (inner and outer, if double sterile barrier design), an indication as to which packages contained actual devices (or simulated devices of similar mass and geometry), and an indication as to which testing is yet to be completed.




PACKAGING – Draft Deficiency – Part 4



Additionally, please provide comprehensive package performance and package stability [test protocols](#) (including predetermined acceptance criteria), [and all currently available test reports](#) and test data.

Establishing that the packaging performance has been adequately validated will help ensure that the SBS will maintain product sterility during shipping and prior to use, minimize the risk of patient infection, and thereby reduce the risk to patient health.



REUSABLE DEVICES — REUSE-LIFE (SERVICE-LIFE)



REUSABLE DEVICE — REUSE-LIFE (SERVICE-LIFE)



Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling

Guidance for Industry and Food and Drug Administration Staff

Document issued on: March 17, 2015

Appendix E of this guidance was updated on June 9, 2017.

This document supersedes: “Labeling Reusable Medical Devices for
Reprocessing in Health Care Facilities: FDA Reviewer Guidance” issued
April 1996.

The draft of this document was issued on May 2, 2011.

For questions regarding devices regulated by the Center for Devices and Radiological Health, contact the Infection Control Devices Branch (INCB) at (301) 796-5580. For questions regarding devices regulated by the Center for Biologics Evaluation and Research (CBER), contact the Office of Communication, Outreach and Development at 800-835-4709 or 240-402-7800.



U.S. Department of Health and Human Services
Food and Drug Administration
Center for Devices and Radiological Health
Center for Biologics Evaluation and Research



REUSABLE DEVICE — REUSE-LIFE (SERVICE-LIFE)



Contains Nonbinding Recommendations

Table of Contents


- I. INTRODUCTION..... 1
- II. BACKGROUND 2
- III. SCOPE 2
 - Exclusions 3
- IV. GENERAL CONSIDERATIONS FOR REUSABLE MEDICAL DEVICES 4
 - A. Design of Reusable Medical Devices 4
 - B. Ensuring the Safety of Reusable Medical Devices 4
- V. GENERAL CONSIDERATIONS FOR REPROCESSING INSTRUCTIONS IN DEVICE LABELING..... 4
 - A. Overview of Reprocessing..... 5

Criterion 5. Reprocessing instructions should be comprehensive.

Comprehensive instructions enable the user to understand precisely how to implement the entire reprocessing procedure safely and effectively. There may be several acceptable formats for instructions.

To ensure the reprocessing instructions are comprehensive, they should include all of the elements below. If any element is not applicable to your device, then you should state this in your premarket submission and provide a justification.

- A. Documentation in 510(k)s..... 29
- B. Documentation in PMAs, HDEs and De Novo Requests 30
- C. Documentation in IDEs..... 30
- APPENDIX A. DEFINITION OF TERMS..... 32
- APPENDIX B. OVERVIEW OF REUSABLE MEDICAL DEVICE REPROCESSING.. 35
- APPENDIX C. EXAMPLES OF STERILIZATION CYCLES USED IN HEALTH CARE SETTINGS..... 36




REUSABLE DEVICE — REUSE-LIFE (SERVICE-LIFE)



5. L. Reuse-Life

The labeling should either

- 1) inform the user **how many times the device can be reused, based on testing**; or




REUSABLE DEVICE — REUSE-LIFE (SERVICE-LIFE)



5. L. Reuse-Life

The labeling should either

- 1) inform the user how many times the device can be reused, based on testing; or
- 2) provide the user with a mechanism or method to ascertain whether the device has exceeded its use-life. In the latter case, the labeling should identify a method to establish that the device is still within performance specifications, as well as instructions for appropriate disposal of devices that fail. For example:




REUSABLE DEVICE — REUSE-LIFE (SERVICE-LIFE)



5. L. Reuse-Life

The labeling should either

- 1) inform the user how many times the device can be reused, based on testing; or
- 2) provide the user with a mechanism or method to ascertain whether the device has exceeded its use-life. In the latter case, the labeling should identify a method to establish that the device is still within performance specifications, as well as instructions for appropriate disposal of devices that fail. For example:
 - labeling that refers to a **device design feature, such as a built-in, automatic pre-check function;**



REUSABLE DEVICE — REUSE-LIFE (SERVICE-LIFE)



5. L. Reuse-Life

The labeling should either

- 1) inform the user how many times the device can be reused, based on testing; or
- 2) provide the user with a mechanism or method to ascertain whether the device has exceeded its use-life. In the latter case, the labeling should identify a method to establish that the device is still within performance specifications, as well as instructions for appropriate disposal of devices that fail. For example:
 - labeling that refers to a device design feature, such as a built-in, automatic pre-check function;
 - labeling that identifies a [performance test that should be passed](#) prior to reuse;




REUSABLE DEVICE — REUSE-LIFE (SERVICE-LIFE)



5. L. Reuse-Life

The labeling should either


- 1) inform the user how many times the device can be reused, based on testing; or
- 2) provide the user with a mechanism or method to ascertain whether the device has exceeded its use-life. In the latter case, the labeling should identify a method to establish that the device is still within performance specifications, as well as instructions for appropriate disposal of devices that fail. For example:
 - labeling that refers to a device design feature, such as a built-in, automatic pre-check function;
 - labeling that identifies a performance test that should be passed prior to reuse;
 - **labeling that recommends visual inspection along with acceptance or failure criteria (e.g., unacceptable deterioration such as corrosion, discoloration, pitting, cracked seals).**



REUSABLE DEVICE — REUSE-LIFE (SERVICE-LIFE)



5. L. Reuse-Life



“Investigating Surgical Instrument Damage: How to ensure your investment is protected©,”
Dr. Matthias Tschoerner, IAHCMM 2021 Annual Conference, Columbus, OH.

- labeling that recommends visual inspection along with acceptance or failure criteria (e.g., unacceptable deterioration such as corrosion, discoloration, pitting, cracked seals).




REUSABLE DEVICE — REUSE-LIFE (SERVICE-LIFE)



5. L. Reuse-Life

Whichever method is chosen, labeling should recommend how to evaluate deterioration in difficult to see areas of complex devices, especially those with lumens (e.g., leak testing).

Reuse-life may also be addressed by validating the number of times the product can be reprocessed and reused and providing this specification in the labeling. If the reuse-life of a device is limited to a specific number of use/reprocessing cycles, the labeling should also describe a specific tracking method for the number of reuse cycles. It may be appropriate for labeling to remind the user that the specific number of reuse cycles is dependent on full compliance with the directions for use of the device.



For additional information, please contact:

Vesa Vuniqi

vesavuniqi@fda.hhs.gov


Patricia Pineda

Ana.PinedaZavaleta@fda.hhs.gov

Steven Turtil

Steven.Turtil@fda.hhs.gov





THANK YOU!

